



PTO COVER LETTER

DOCKET NO.: 213126US0X

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Re: Serial No.: 09/931,951
Applicant(s): Nobuhiro SATO, et al.
Filing Date: AUGUST 20, 2001
For: THERAPEUTIC AGENT FOR ULCERATIVE
COLITIS
GAU: 1645
Examiner: V. FORD



ATTORNEYS AT LAW
NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM
VINCENT K. SHIER, Ph.D.
(703) 413-3000
VSHIER@OBLON.COM

RECEIVED

FEB 06 2002

SIR:

Attached hereto for filing are the following papers:


TECH CENTER 1600/2900

1. Response to Restriction Requirement

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. §1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Attorney of Record
Registration No. 24,618

Vincent K. Shier, Ph.D.
Registration No. P-50,552

Tel.: 703-413-3000
Fax: 703-413-2220
NFO:VKS:ksh
I:\atty\VKS\213126US-PTO Cvr Ltr.wpd



22850

DOCKET NO.: 213126USX



*Electron / #6
J 2/16/02*

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Nobuhiro SATO, et al.

SERIAL NO.: 09/931,951

FILED: AUGUST 20, 2001

FOR: THERAPEUTIC AGENT FOR ULCERATIVE COLITIS

:

: GROUP ART UNIT: 1645

:

: EXAMINER: V. FORD

RECEIVED

FEB 06 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated January 4, 2002, Applicants elect, with traverse, Group V, Claim 14, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

- Group I: Claims 1-8, drawn to a pharmaceutical composition and vaccine;
- Group II: Claim 9, drawn to a method of screening a drug;
- Group III: Claim 10, drawn to a method of screening a therapeutic agent;
- Group IV: Claims 11-13, drawn to an animal model;
- Group V: Claim 14, drawn to a method of diagnosis of ulcerative colitis; and
- Group VI: Claim 15, drawn to an agent for making a diagnosis of ulcerative colitis.

✓
Applicants elect, with traverse, Group V, Claim 14.